Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Mark E, Gurney"'
Autor:
Jordan E. Norris, Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney, Lauren E. Ethridge
Publikováno v:
Molecular Autism, Vol 15, Iss 1, Pp 1-6 (2024)
Abstract Fragile X syndrome (FXS) is a rare neurodevelopmental disorder caused by a CGG repeat expansion ≥ 200 repeats in 5’ untranslated region of the FMR1 gene, leading to intellectual disability and cognitive difficulties, including in the dom
Externí odkaz:
https://doaj.org/article/c3d257b9fa424b7f95d4a3eeaa327d8e
Autor:
QuanQiu Wang, Pamela B. Davis, Xin Qi, Shu G. Chen, Mark E. Gurney, George Perry, P. Murali Doraiswamy, Rong Xu
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-13 (2021)
Abstract Background Interactions between the gut microbiota, microglia, and aging may modulate Alzheimer’s disease (AD) pathogenesis but the precise nature of such interactions is not known. Methods We developed an integrated multi-dimensional, kno
Externí odkaz:
https://doaj.org/article/8e709b3481924b4487ab57ec171a616d
Publikováno v:
Neurobiology of Disease, Vol 159, Iss , Pp 105485- (2021)
Fragile X Syndrome (FXS) is caused by silencing the FMR1 gene which results in intellectual disability, hyperactivity, sensory hypersensitivity, autistic-like behavior, and susceptibility to seizures. This X-linked disorder is also associated with re
Externí odkaz:
https://doaj.org/article/b090f63367e046bca7d8ce9077f039f8
Autor:
Yulu Wang, Shichao Gao, Victor Zheng, Ling Chen, Min Ma, Shichen Shen, Jun Qu, Hanting Zhang, Mark E. Gurney, James M. O’Donnell, Ying Xu
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
A global, quantitative proteomics/systems-biology analysis of the selective pharmacological inhibition of phosphodiesterase-4D (PDE4D) revealed the differential regulation of pathways associated with neuroplasticity in memory-associated brain regions
Externí odkaz:
https://doaj.org/article/b32281c76e4043ce81ec97cfa518955f
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229819 (2020)
This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent is associated with lower risk for Alzheimer's disease
Externí odkaz:
https://doaj.org/article/47b1edd7cc4c4e7bbb3ff51ff537fa50
Autor:
Mark E. Gurney
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 12 (2019)
Recent, large-scale, genome-wide association studies (GWAS) provide a first view of the genetic fine structure of cognitive performance in healthy individuals. These studies have pooled data from up to 1.1 million subjects based on simple measures of
Externí odkaz:
https://doaj.org/article/806d955a9f0540c6af6b9f1d80f86ade
Autor:
Mary Brophy, Xin Qi, Pamela B. Davis, Shu G. Chen, Mark E. Gurney, Jaime Ramos-Cejudo, Ricardo S. Osorio, Nathanael Fillmore, Maureen Dubreuil, Chunlei Zheng, Wei Qiao Qiu, Rhoda Au, Rong Xu, George Perry, Nhan Do
Publikováno v:
Alzheimers Dement
Introduction Tumor necrosis factor (TNF) inhibitors are widely used to treat rheumatoid arthritis (RA) and their potential to retard Alzheimer's disease (AD) progression has been reported. However, their long-term effects on the dementia/AD risk rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c0afdfbc6a4eaada1dcdb4af29b62c
https://doi.org/10.1002/alz.12465
https://doi.org/10.1002/alz.12465
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0178013 (2017)
Traumatic brain injury (TBI) initiates a deleterious inflammatory response that exacerbates pathology and worsens outcome. This inflammatory response is partially mediated by a reduction in cAMP and a concomitant upregulation of cAMP-hydrolyzing phos
Externí odkaz:
https://doaj.org/article/a3f2de3e7184435ca8231185ecd423a3
Autor:
Melody A Reese, Lauren E. Ethridge, Abigail H Outterson, Claire Michalak, Jeremiah Furman, Mark Harnett, Mark E Gurney, Elizabeth Berry-Kravis, Scott A Reines
Publikováno v:
Nature Medicine. 27:862-870
The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral outcomes in patients with fragile X syndrome (FXS). This phase 2 trial was a 24-week random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c083ca5e5b6dda5c48c1dc091556aaae
https://doi.org/10.1038/s41591-021-01321-w
https://doi.org/10.1038/s41591-021-01321-w
Publikováno v:
Oncogene
Cyclic nucleotide phosphodiesterases (PDE) break down cyclic nucleotides such as cAMP and cGMP, reducing the signaling of these important intracellular second messengers. Several unique families of phosphodiesterases exist, and certain families are c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acfb529906e519c858e321f6fb1e75a9
https://doi.org/10.1038/s41388-020-1258-8
https://doi.org/10.1038/s41388-020-1258-8